Upregulating MMP‑1 in carcinoma‑associated fibroblasts reduces the efficacy of Taxotere on breast cancer synergized by Collagen IV

Cui,Qingyu; Wang,Bixiao; Li,Kaifu; Sun,Haichen; Hai,Tao; Zhang,Yan; Kang,Hua

doi:10.3892/ol.2018.9092

Upregulating MMP‑1 in carcinoma‑associated fibroblasts reduces the efficacy of Taxotere on breast cancer synergized by Collagen IV

Authors:
- Qingyu Cui
- Bixiao Wang
- Kaifu Li
- Haichen Sun
- Tao Hai
- Yan Zhang
- Hua Kang
View Affiliations

Affiliations: Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China, Surgery Laboratory, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China
Published online on: July 5, 2018 https://doi.org/10.3892/ol.2018.9092
Pages: 3537-3544
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is an important comprehensive treatment for breast cancer, which targets micro‑environment of tumors as well as their characterisitcs. A previous microarray analysis revealed that matrix metalloproteinase (MMP)‑1 was highly upregulated in carcinoma-associated fibroblasts (CAFs) prior to and following treatment with Taxotere under co‑culture conditions. However, whether the chemotherapeutic effects of Taxotere were influenced by the changes in MMP‑1 remained unclear. The purpose of the present study was to investigate the impact and mechanism of CAFs in regulating the efficacy of Taxotere on breast cancer cells. CAFs isolated from primary invasive ductal human breast tumors following surgical resection, were used in co‑culture with MDA‑MB‑231 cells to simulate the tumor micro‑environment. Following the addition of Taxotere, changes in MMP‑1 gene and protein expression were assessed by reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. Proliferation, invasion and apoptosis assays revealed that when MMP‑1 was upregulated in CAFs, the therapeutic efficacy of Taxotere was reduced in breast cancer cells. Chemosensitivity was significantly increased when MMP‑1 expression was inhibited by GM6001. In addition, Collagen IV was upregulated in CAFs following chemotherapy and protected breast cancer cells against chemotherapeutic side effects. Collagen IV expression significantly decreased, as well as MMP‑1 expression when GM6001 was added. Proliferation and invasion assays demonstrated that the exogenous addition of Collagen IV weakend the chemotherapeutic effect of Taxotere on breast tumor cells. Overall, the results revealed that in CAFs, MMP‑1 synergized with Collagen IV as a key gene in regulating the chemotherapeutic effect of Taxotere on breast tumor cells and served an important role in reducing the efficacy of Taxotere on breast cancer, potentially via the transforming growth factor‑β signaling pathway. These fidings provide a theoretical basis for the mechanism of CAFs in reducing the chemotherapeutic effect of Taxotere on breast cancer cells and a novel approach for enhancing the chemosensitivity of tumors.

View Figures

View References

1	Tao Z, Shi A, Lu C, Song T, Zhang Z and Zhao J: Breast cancer: Epidemiology and etiology. Cell Biochem Biophys. 72:333–338. 2015. View Article : Google Scholar : PubMed/NCBI
2	Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
3	Carrara GF, Scapulatempo-Neto C, Abrahão-Machado LF, Brentani MM, Nunes JS, Folgueira MA and Vieira RA: Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up. Clinics (Sao Paulo). 72:134–142. 2017. View Article : Google Scholar : PubMed/NCBI
4	Tafe LJ: Molecular mechanisms of therapy resistance in solid tumors: Chasing ‘moving’ targets. Virchows Arch. 471:155–164. 2017. View Article : Google Scholar : PubMed/NCBI
5	Nguyen LV, Vanner R, Dirks P and Eaves CJ: Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143. 2012. View Article : Google Scholar : PubMed/NCBI
6	Clevers H: The cancer stem cell: Premises, promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
7	Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA, Neves JH and Machado-Santelli GM: The multiple facets of drug resistance: One history, different approaches. J Exp Clin Cancer Res. 33:372014. View Article : Google Scholar : PubMed/NCBI
8	Luo H, Tu G, Liu Z and Liu M: Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression. Cancer Lett. 361:155–163. 2015. View Article : Google Scholar : PubMed/NCBI
9	Tao L, Huang G, Song H, Chen Y and Chen L: Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett. 14:2611–2620. 2017. View Article : Google Scholar : PubMed/NCBI
10	Ashida S, Kawada C and Inoue K: Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR. Oncol Lett. 14:6533–6542. 2017.PubMed/NCBI
11	Du H and Che G: Genetic alterations and epigenetic alterations of cancer-associated fibroblasts. Oncol Lett. 13:3–12. 2017. View Article : Google Scholar : PubMed/NCBI
12	Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ and Munshi HG: Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 71:1019–1028. 2011. View Article : Google Scholar : PubMed/NCBI
13	Burdelya LG, Komarova EA, Hill JE, Browder T, Tararova ND, Mavrakis L, DiCorleto PE, Folkman J and Gudkov AV: Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res. 66:9356–9361. 2006. View Article : Google Scholar : PubMed/NCBI
14	Rong G, Kang H, Wang Y, Hai T and Sun H: Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs). PLoS One. 8:e709602013. View Article : Google Scholar : PubMed/NCBI
15	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
16	Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J and Barrio MM: Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther. 13:1123–1140. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chabottaux V and Noel A: Breast cancer progression: Insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis. 24:647–656. 2007. View Article : Google Scholar : PubMed/NCBI
18	Li K, Kang H, Wang Y, Hai T, Rong G and Sun H: Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology. Med Oncol. 33:642016. View Article : Google Scholar : PubMed/NCBI
19	Aboussekhra A: Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int J Dev Biol. 55:841–849. 2011. View Article : Google Scholar : PubMed/NCBI
20	Sambi M, Haq S, Samuel V, Qorri B, Haxho F, Hill K, Harless W and Szewczuk MR: Alternative therapies for metastatic breast cancer: Multimodal approach targeting tumor cell heterogeneity. Breast Cancer (Dove Med Press). 9:85–93. 2017.PubMed/NCBI
21	Kubo N, Araki K, Kuwano H and Shirabe K: Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol. 22:6841–6850. 2016. View Article : Google Scholar : PubMed/NCBI
22	Madar S, Goldstein I and Rotter V: ‘Cancer associated fibroblasts’-more than meets the eye. Trends Mol Med. 19:447–453. 2013. View Article : Google Scholar : PubMed/NCBI
23	Junttila MR and de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
24	Perez EA: Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat. 114:195–201. 2009. View Article : Google Scholar : PubMed/NCBI
25	Dittmer J and Leyh B: The impact of tumor stroma on drug response in breast cancer. Semin Cancer Biol. 31:3–15. 2015. View Article : Google Scholar : PubMed/NCBI
26	Shekhar MP, Santner S, Carolin KA and Tait L: Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol. 170:1546–1560. 2007. View Article : Google Scholar : PubMed/NCBI
27	Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L and Nelson PS: Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 18:1359–1368. 2012. View Article : Google Scholar : PubMed/NCBI
28	Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, et al: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2⁺ breast cancer. Cancer Res. 77:3280–3292. 2017. View Article : Google Scholar : PubMed/NCBI
29	Faller WJ, Rafferty M, Hegarty S, Gremel G, Ryan D, Fraga MF, Esteller M, Dervan PA and Gallagher WM: Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res. 20:392–400. 2010.PubMed/NCBI
30	Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, et al: Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene. 22:6408–6423. 2003. View Article : Google Scholar : PubMed/NCBI
31	Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, Braghetta P, Columbaro M, Volpin D, Bressan GM, et al: Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet. 35:367–371. 2003. View Article : Google Scholar : PubMed/NCBI
32	Tokes AM, Szasz AM, Farkas A, Toth AI, Dank M, Harsanyi L, Molnar BA, Molnar IA, Laszlo Z, Rusz Z and Kulka J: Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin Cancer Res. 15:731–739. 2009. View Article : Google Scholar : PubMed/NCBI
33	Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T and Morin PJ: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 3:377–386. 2003. View Article : Google Scholar : PubMed/NCBI
34	Tatti O, Vehvilainen P, Lehti K and Keski-Oja J: MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res. 314:2501–2514. 2008. View Article : Google Scholar : PubMed/NCBI
35	Xu Z, Wang S, Wu M, Zeng W, Wang X and Dong Z: TGFβ1 and HGF protein secretion by esophageal squamous epithelial cells and stromal fibroblasts in oesophageal carcinogenesis. Oncol Lett. 6:401–406. 2013. View Article : Google Scholar : PubMed/NCBI
36	Bates AL, Pickup MW, Hallett MA, et al: Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases. J Pathol. 2015.235(5): 773–783. View Article : Google Scholar : PubMed/NCBI